Andreas Vegge, PhD

Project Vice President, Amycretin Cardiometabolics at Novo Nordisk

Speaker

Andreas Vegge is Project Vice President (PVP) in Cardiometabolic Clinical Development and Project Leadership at Novo Nordisk A/S, Denmark, and head of the amycretin program. He has been responsible for the amycretin program since entry into the research portfolio, overseeing lead optimization and selection, IND-enabling activities and the execution of phase 1 and 2, while ensuring readiness for phase 3. Andreas joined Novo Nordisk in 2012 in Diabetes Pharmacology, and has since held various positions of increasing scientific and leadership responsibility. Previously as PVP in Research and Early Development leading programs across therapeutic areas and molecular modalities, before transitioning into Development organization to continue to lead amycretin into late stage development.

Andreas holds a Doctor of Veterinary Medicine (DVM) and a PhD in in vivo pharmacology from the University of Copenhagen, has performed research at University of Cambridge and Baylor College of Medicine and holds a postgraduate Diploma in Pharmaceutical Medicine from the University of Basel. Andreas lectures in translational pharmacology & drug development at University of Copenhagen, is a co-inventor of numerous patents and has co-authored 25+ scientific publications, including in leading scientific journals such as The Lancet, Science, Nature Biotechnology and Science Translational Medicine.